Aptus Pharma came to market through an SME IPO that opened on 23 September 2025 and closed on 25 September 2025, and the shares listed on 30 September 2025 on BSE SME. The price band was ₹65 to ₹70 per share and one lot was 2000 shares, so the minimum application was ₹1,40,000. The issue size was ₹13.02 crore. The whole issue was fresh shares, so the money raised went to the company.
Bigshare Services Pvt Ltd was the registrar to the issue, and Interactive Financial Services Ltd was the lead manager.
As of 25 September 2025.
| Day |
|---|
| 1 |
| 2 |
| 3 |
Established in 2010, Aptus Pharma Ltd is a company dealing with marketing, and distribution of finished pharmaceutical formulations. The company deals with manufacturers and distributors of a wide range of pharmaceutical formulations catering to various therapeutic categories: antacids & PPIs, pain management, anti-inflammatories, antibiotics, cardiology & antidiabetics, neuropsychiatry, dental, injectable parenterals, syrups, nutraceuticals, sachets, etc. Products: Aptus Pharma: Deals with acute therapies i.e, anti-infectives, pain management, etc. Aptus CD care: Deals with chronic therapies. Aptus Wellcare: Wellness and nutraceutical products.
Aptus Global: Export in overseas market. The company has 194 formulations of medicines in over eleven therapeutic segments as of March 31, 2025. Its warehouse is spread over 15,732 sq. Feet and 1989 sq. feet in Ahmedabad, Gujarat. Its distribution model has 125 direct and sub distributors and a sales force of 54 field staff. The company had 70 employees as of March 31, 2025.
As described in the offer document.
| Metric | 31-Mar-25 | 31-Mar-24 | 31-Mar-23 |
|---|
Tejash Maheshchandra Hathi, Chatrabhuj Vallabhbhai Butani, Kapilbhai Hasmukhbhai Chandarana, Ghanshyam Vinubhai Pansuriya, Milly Chetan Lalseta, Riddhish Natwarlal Tanna, Gaurang Rameshchandra Thakker, Kripaliben Mayank Thakker, Kunjal Piyushbhai Unadkat. Promoter holding 100% before the issue and 72.89% after.
Work out the listing gain for this SME IPO
If the retail portion is not fully subscribed, every valid application is allotted in full. If it is oversubscribed, SEBI's rules require that as many applicants as possible receive at least one lot, so the shares are allotted by a computerised lottery across all valid applications, one lot each, until the retail portion is exhausted. Applying for more lots does not improve your chance in a lottery; it only increases what you receive if the issue is under-subscribed.
The basis of allotment document, published by the registrar on the allotment date, states the ratio: for example, one applicant in seven received one lot.
Allotment status is published by the registrar on its website, searchable by PAN, application number or demat account, and also on the exchange's website. Allotted shares are credited to the demat account the day before listing, and blocked money for unsuccessful applications is released the same day. The Rupix app can check allotment status by PAN once the registrar publishes it.
Shares list within three working days of the issue closing. On listing day the exchanges run a special pre-open session from nine o'clock, during which orders are collected and an opening price is discovered from them; trading in the share begins after that, usually around ten. The opening price is the listing price that appears on this page once the issue has listed, and the listing gain or loss is the difference between it and the issue price.
For a mainboard issue, the share then trades in the normal way with the exchange's price band for a new listing. For an SME issue, shares trade in lots rather than one at a time, and the market can be thin, so selling on listing day is not always possible at the opening price. Capital gains on shares sold within a year of allotment are short-term and taxed at the short-term rate.
Aptus Pharma IPO was a ₹13.02 crore book-built issue, made up entirely of a fresh issue. It was priced at ₹65–₹70 per share with a lot size of 2,000 shares; the minimum retail application was 4,000 shares (₹2,80,000). The IPO was open from September 23 to September 25, 2025 and was subscribed 22.4x. Shares listed on BSE SME on September 30, 2025 at ₹80.80, a 15.4% premium to the issue price of ₹70. Bigshare Services Pvt Ltd is the registrar.
Interactive Financial Services Ltd. is the book running lead manager.
The price band of Aptus Pharma IPO is ₹65 to ₹70 per share.
The lot size of Aptus Pharma IPO is 2000 shares.
The minimum investment for Aptus Pharma IPO is approximately ₹1,40,000 based on the upper price band.
The allotment date of Aptus Pharma IPO is Sep 26, 2025.
You can check Aptus Pharma IPO allotment status on the registrar or stock exchange websites using your PAN or application number after allotment. You can also check the Aptus Pharma IPO allotment status on Rupix for quick and easy access.
₹65 to ₹70 per share, against a face value of ₹10. Most applicants bid at the cut-off price, the top of the band, so that the application was valid whatever price the issuer finally fixed.
One lot was 2000 shares, and every application had to be a whole number of lots. At the top of the band that made the minimum application ₹1,40,000. After listing, SME shares also trade in lots rather than one share at a time.
₹1,40,000, for one lot of 2000 shares at the top of the price band. The amount was blocked in the applicant's bank account through ASBA or a UPI mandate while the issue was open, and released on the allotment date to applicants who were not allotted shares.
It opened on 23 September 2025 and closed on 25 September 2025.
The basis of allotment was published on 26 September 2025 by Bigshare Services Pvt Ltd, and allotted shares were credited to demat accounts before listing.
The shares listed on 30 September 2025 on BSE SME.
The issue size was ₹13.02 crore. The fresh issue was 18,60,000 shares (aggregating up to ₹13.02 crore).